drugset / Trial / NCT04193293
A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer
NaSingle-groupOpen-labelTreatment
Summary
This study was designed to assess the safety and preliminary efficacy of duvelisib in combination with pembrolizumab in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
Timeline
- Start
- 2020-06-01
- Primary completion
- 2020-12-10
- Completion
- 2020-12-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Duvelisib | Small molecule | — | — |
| Subject | Pembrolizumab | Monoclonal antibody | — | — |